Dynamic DNA methylation across diverse human cell lines and tissues by Varley, Katherine E. et al.
 10.1101/gr.147942.112Access the most recent version at doi:
 2013 23: 555-567 originally published online January 16, 2013Genome Res.
 
Katherine E. Varley, Jason Gertz, Kevin M. Bowling, et al.
 
tissues
Dynamic DNA methylation across diverse human cell lines and
 
 
Material
Supplemental  http://genome.cshlp.org/content/suppl/2012/12/18/gr.147942.112.DC1.html
Related Content
 
 Genome Res. September , 2012 22: 1723-1734
Aaron Arvey, Phaedra Agius, William Stafford Noble, et al.
factor binding
specific transcription−Sequence and chromatin determinants of cell-type
 
 Genome Res. September , 2012 22: 1680-1688
Hao Wang, Matthew T. Maurano, Hongzhu Qu, et al.
Widespread plasticity in CTCF occupancy linked to DNA methylation
 
 Genome Res. September , 2012 22: 1658-1667
Chao Cheng, Roger Alexander, Renqiang Min, et al.
transcription factor binding data
Understanding transcriptional regulation by integrative analysis of
 
 Genome Res. September , 2012 22: 1798-1812
Jie Wang, Jiali Zhuang, Sowmya Iyer, et al.
bound by 119 human transcription factors
Sequence features and chromatin structure around the genomic regions
References
 http://genome.cshlp.org/content/23/3/555.full.html#ref-list-1
This article cites 69 articles, 24 of which can be accessed free at:
License
Commons 
Creative
.http://creativecommons.org/licenses/by-nc/3.0/described at
asa Creative Commons License (Attribution-NonCommercial 3.0 Unported License), 
). After six months, it is available underhttp://genome.cshlp.org/site/misc/terms.xhtml
for the first six months after the full-issue publication date (see
This article is distributed exclusively by Cold Spring Harbor Laboratory Press
 http://genome.cshlp.org/subscriptions
 go to: Genome ResearchTo subscribe to 
© 2013, Published by Cold Spring Harbor Laboratory Press
 Cold Spring Harbor Laboratory Press on April 4, 2013 - Published by genome.cshlp.orgDownloaded from 
service
Email alerting
 click heretop right corner of the article or
Receive free email alerts when new articles cite this article - sign up in the box at the
 http://genome.cshlp.org/subscriptions
 go to: Genome ResearchTo subscribe to 
© 2013, Published by Cold Spring Harbor Laboratory Press
 Cold Spring Harbor Laboratory Press on April 4, 2013 - Published by genome.cshlp.orgDownloaded from 
Resource
Dynamic DNA methylation across diverse human cell
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As studies of DNA methylation increase in scope, it has become evident that methylation has a complex relationship
with gene expression, plays an important role in defining cell types, and is disrupted in many diseases. We describe
large-scale single-base resolution DNA methylation profiling on a diverse collection of 82 human cell lines and tissues
using reduced representation bisulfite sequencing (RRBS). Analysis integrating RNA-seq and ChIP-seq data illumi-
nates the functional role of this dynamic mark. Loci that are hypermethylated across cancer types are enriched for
sites bound by NANOG in embryonic stem cells, which supports and expands the model of a stem/progenitor cell
signature in cancer. CpGs that are hypomethylated across cancer types are concentrated in megabase-scale domains
that occur near the telomeres and centromeres of chromosomes, are depleted of genes, and are enriched for cancer-
specific EZH2 binding and H3K27me3 (repressive chromatin). In noncancer samples, there are cell-type specific
methylation signatures preserved in primary cell lines and tissues as well as methylation differences induced by cell
culture. The relationship between methylation and expression is context-dependent, and we find that CpG-rich en-
hancers bound by EP300 in the bodies of expressed genes are unmethylated despite the dense gene-body methylation
surrounding them. Non-CpG cytosine methylation occurs in human somatic tissue, is particularly prevalent in brain
tissue, and is reproducible across many individuals. This study provides an atlas of DNA methylation across diverse
and well-characterized samples and enables new discoveries about DNA methylation and its role in gene regulation
and disease.
[Supplemental material is available for this article.]
In the early 1980s, several groups observed that the covalent ad-
dition of a methyl group to the cytosine base in mammalian ge-
nomic DNA at certain loci is associated with differential gene
expression of nearby genes (Razin and Riggs 1980; Sutter and
Doerfler 1980; van der Ploeg and Flavell 1980). This led to decades
of research deciphering the patterns and purpose of this fifth DNA
base in the human genome. It is an ongoing challenge to map the
locations of methylated cytosines across the genome and to un-
derstand their roles in cell-type specific gene regulation (Ghosh
et al. 2010), the establishment of gene expression patterns for
stable differentiation (Lei et al. 1996; Okano et al. 1999; Jackson
et al. 2004; Blelloch et al. 2006; Ji et al. 2010; Kim et al. 2010), and
disease, including cancer where vast changes in DNAmethylation
patterns occur (Laird and Jaenisch 1994; Ushijima 2005; Sharma
et al. 2010; Tsai and Baylin 2011). Bisulfite sequencing provides
the most direct and highest resolution method to quantify DNA
methylation in the genome, enabling the ability to calculate the
fraction of molecules that are methylated at each individual
cytosine sequenced (Frommer et al. 1992). The advent of next-
generation DNA sequencing technologies has prompted the de-
velopment of methods that take advantage of this vastly increased
throughput, using bisulfite sequencing to query large subsets of
the human genome (Meissner et al. 2008) and even whole human
genomes (Cokus et al. 2008; Lister et al. 2009; Laurent et al. 2010;
Li et al. 2010; Hansen et al. 2011; Berman et al. 2012; Hon et al.
2012).
The goal of this study was to generate a high-quality com-
pendium of DNA methylation data across a large number of hu-
man cell lines and tissues. Reduced representation bisulfite se-
quencing (RRBS) was chosen because it provides quantitative,
single-base resolutionmethylation profiles for a large subset of the
human genome that is enriched for genic regions and CpG islands
(CGIs) (Meissner et al. 2008). Other genomic assays have been
performed in these samples as part of The ENCODE Project (The
ENCODE Project Consortium 2007, 2011, 2012), providing a rich
resource for integrated analysis of DNA methylation, gene ex-
pression, transcription factor binding, and chromatin modifica-
tions. We demonstrate that comparisons of methylation profiles
across the diverse collection of samples in this study can be used to
investigate cancer-associated methylation defects, cell-type specific
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methylation, and epigenetic changes induced by cell culture. We
quantify the reciprocal relationships of promoter and gene body
methylation to expression levels and present the identification of
a DNA methylation signature of intragenic (gene body) tran-
scriptional enhancers marked by EP300 that clarifies the in-
terpretation of gene body methylation. We report the discovery
of reproducible non-CpG cytosine methylation in human so-
matic tissue, particularly in adult human brain tissues. The data
described here provide an atlas of DNA methylation for in-
vestigating how this epigenetic mark relates to other molecular
and phenotypic characteristics within these diverse cell types,
including many commonly used cell line models. The data are
readily available for visualization and analysis using the UCSC
Genome Browser (Fujita et al. 2011; Raney et al. 2011) and will
provide a valuable resource for future comparisons to other cell
types, disease states, and functional genomic assays.
Results
Quantifying DNA methylation
We modified a previously published protocol for RRBS (Meissner
et al. 2008) to create a streamlined workflow for this larger-scale
implementation (Supplemental Fig. S1). For each reference cyto-
sine sequenced, we computed the percentage of reads in which the
cytosine was methylated (remained a C after bisulfite treatment)
out of the total reads covering that position (Supplemental Fig. S2).
This percent methylated (PM) value represents the percentage of
molecules that were methylated at each cytosine.
In replicate growths of the humanmyeloid cell line K562, we
found that lower read depth provided less reproducible measure-
ments of PM between replicates. When restricted to CpGs with at
least 103 coverage, the reproducibility of PMmeasurements across
the full range of values improved between replicates (r = 0.987) and
resulted in an average of 3.96 PM difference per CpG between
replicates (Supplemental Fig. S3A). The resulting PM measure-
ments were highly correlated with values obtained from an array-
based methylation assay (Illumina Methyl450K, r = 0.954) (Sup-
plemental Fig. S3B). We performed RRBS on 82 human cell lines
and tissues in duplicate (sample information in Supplemental
Table S1) and obtained at least 103 coverage for an average of
700,000 CpGs in each sample. TheMspI restriction digest utilized
for RRBS enriches for CpG-dense regions of the genome, in-
cluding genes (twofold enrichment) and CpG islands (111-fold
enrichment).
Global observations
We found that all samples, regardless of the disease state or tissue
type, had similar distributions of methylation among the assayed
CpGs (mean of pairwise R2 = 0.96) (Supplemental Fig. S3C). In each
sample, 5%–15% of assayed CpGs were completely methylated
(PM $ 90), and 65%–80% of assayed CpGs were unmethylated
(PM # 10). This consistency could appear because the same CpGs
are always methylated in all samples, or it could result from the
same net amount of methylation placed on different loci between
samples. Our data set supports the latter; the PM values of in-
dividual CpGs varied substantially across cell lines and tissues.
Only 4% (27,053) of CpGs are unmethylated (#10 PM) across all
cell lines and tissues that we assayed, and these are located near the
transcription start sites (x2, P < 0.0004) of geneswith housekeeping
functions (P < 1.353 1010). The remaining 670,000 CpGs that we
assayed exhibited differential methylation in this study, providing
a rich data set for investigating epigenetic patterns.
To characterize cell-type specific methylation patterns, we
analyzed 440,974 autosomal CpGs with at least 103 coverage in at
least 90% of the samples. We performed unsupervised hierarchical
clustering on the PM values for the top 5% of CpGs with the most
variablemethylation (N = 22,696, s$ 32.6). The samples all paired
with their replicates and clustered into clades with distinct meth-
ylation patterns, and these clades corresponded to distinct types of
samples, namely cancer cell lines, primary cell lines, tissues, and
blood leukocytes (Fig. 1A; detailed tree in Supplemental Fig. S4).
We divided these most variable CpGs based on whether they are
located in gene regulatory regions (<2000 bp from the transcrip-
tion start site) or in the body of genes (>2000 bp from the tran-
scription start site) and found that both subsets recapitulate the
classification of samples in the four clades (Supplemental Fig. S5).
To determine if the detection of cell-type specific differences would
be confounded by epigenetic variability introducedwhen cell lines
were grown in different ENCODE Consortium laboratories, we
obtained growth replicates of the same cell lines from different
laboratories. We found that they clustered together based on cell
type, not laboratory. Furthermore, for a particular cell type, repli-
cates from within a lab and replicates grown in distant labs were
equally similar (Supplemental Fig. S6).
Aberrant methylation across cancer cell lines
The dominant signal in this data set is cancer-specific hyper-
methylation found at 66,570CpGs in the cancer cell lines (Fig. 1A),
including lines derived from breast, prostate, lung, ovarian, en-
dometrial, liver, and pancreatic cancer, as well as neuroblastoma
and several leukemias (Kolmogorov-Smirnov, P < 13 107). Of the
loci that are hypermethylated across cancers, 48,787 (73%) reside
in CGIs (Table 1) and represent a significant portion of the 148,465
island CpGs assayed (33% vs. expected 15%, Fisher’s exact test,
P < 0.05). The observation of hypermethylation at CGIs across the
genome, regardless of their proximity to genes, in 18 diverse cancer
cell lines is consistent with reports of a CpG island methylator
phenotype (CIMP) that was first described in colorectal cancer
(Toyota et al. 1999) and has since been documented in many
cancer types (Teodoridis et al. 2008; Liu et al. 2011; Chen et al.
2012; Turcan et al. 2012). An additional 7377 (11%) nonisland
CpGs are significantly hypermethylated in cancer, and these reside
in promoters and bodies of genes encoding proteins with se-
quence-specific DNA binding transcription factor activity (hyper-
geometric enrichment for GO:0003700, P = 5.43 1015) (Table 1).
The presence of increased methylation in both the promoter and
gene body of these transcription factor genes indicates dysregula-
tion of methylation at these genes in cancer cell lines.
It has been observed that hypermethylation in cancer is
enriched at loci that in embryonic stem cells (ESCs) are unmeth-
ylated, have bivalent chromatin marks, and are reversibly re-
pressed by the Polycomb Repressive Complex. This observation
has led to the model of a stem/progenitor cell signature in cancer
(Ohm et al. 2007; Schlesinger et al. 2007; Widschwendter et al.
2007; Easwaran et al. 2012). We determined the overlap between
the loci that are hypermethylated across the cancer cell lines in our
data set and the location of binding sites for 149 transcription
factors that were assayed by chromatin immunoprecipitation se-
quencing (ChIP-seq) experiments performed by our lab and others
in The ENCODE Project Consortium. For each transcription factor
that overlapped loci that are hypermethylated in cancer cell lines,
556 Genome Research
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we report the enrichment and statistics in Supplemental Table S2.
Consistent with previous reports, we found that hypermethylated
CpGs have a significant overlap with loci that are bound by SUZ12
in ESCs, a component of Polycomb Repressive Complex 2 (Fisher’s
exact test, Benjamini–Hochberg (BH)-adjusted, P = 9.273 10142).
The corepressor CTBP2 was also enriched at these sites and sig-
Figure 1. Methylation patterns distinguish cell types and reveal aberrant hypermethylation across cancers. (A) Unsupervised hierarchical clustering of
the top 5%of CpGs with themost varyingmethylation across 82 samples distinguishes four major clades, identified as cancer cell lines, tissues, primary cell
lines, and blood leukocytes. (B) Loci that are hypermethylated across cancers are significantly enriched for sites that are bound by NANOG in embryonic
stem cells. UCSC Genome Browser visualization of the SFRP2 gene showing DNAmethylation data, NANOG binding sites in the embryonic stem cell line
H1-hESC (H1-hESC), and RNA-seq data. The color in the RRBS track indicates the percent of molecules that are methylated at each CpG position. (Red)
100%, (yellow) 50%, (green) 0%. Hypermethylation across the cancers occurs in the SFRP2 gene promoter where NANOG, a transcription factor, binds in
H1-hESC. NANOG binding in H1-hESC is visualized as green peaks in both ChIP-seq replicates, and peak boundaries are depicted as black and gray boxes
below the raw signal (darker boxes indicate amore significant peak). The RNA-seq data demonstrate that SFRP2 is expressed in H1-hESC and not expressed
in the cancer cell lines (HeLa, HepG2, MCF7, and HCT116).
Dynamic DNA methylation across human tissues
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nificantly overlapped SUZ12-bound loci in ESCs (Fisher’s exact
test, BH-adjusted, P = 9.75 3 1020). Additionally, we discovered
that hypermethylated loci were also enriched for sites where
NANOG is bound in ESCs, which is a transcription regulator es-
sential for maintaining pluripotency in ESCs (Fisher’s exact test,
BH-adjusted, P = 4.06 3 104). The hypermethylated NANOG
binding sites do not overlap the SUZ12-bound loci, and the genes
nearest the hypermethylated NANOG binding sites are enriched
for genes that are overexpressed in human ESCs (P = 6.64 3 105)
(Ben-Porath et al. 2008). These observations support the role of
embryonic transcriptional regulators in directing aberrant meth-
ylation that leads to cancer but add complexity to the model. In
contrast to the polycomb repressive complex recruiting hyper-
methylation in cancer to persistently silence differentiation-
inducing genes, our results suggest that hypermethylation also
occurs at NANOG-bound loci that are active in ESCs. While these
are seemingly opposing effects, it is possible that bothmechanisms
lead to tumorigenesis by silencing genes that lead to differentia-
tion, as well as silencing genes that control the stable, nonneo-
plastic division of a pluripotent cell. This is supported by the ob-
servation that NANOG binding site hypermethylation in cancer
occurs at genes enriched for transcription factor activity (P = 9.783
105), including developmental regulators such as FOXD3, a nega-
tive regulator of cell cycle (Abel and Aplin 2010), and CDX2, whose
silencing is associated with cancer progression (Huang et al. 2012;
Knosel et al. 2012). Figure 1B depicts another example, the SFRP2
gene, a modulator of Wnt signaling, whose promoter is unmeth-
ylated and bound by NANOG in the H1 ESCs where the gene is
expressed. In cancer, the NANOG binding site in the promoter is
methylated, and the gene is silenced.
Hypomethylation across the genome has been reported in
cancer (Irizarry et al. 2009; Hansen et al. 2011; Berman et al. 2012;
Hon et al. 2012). Although RRBS enriches for CpG-rich regions of
the genome that tend to be hypermethylated in cancer, we also
query thousands of positions in low CpG-density regions. We
detected 6691 positions that were significantly hypomethylated
across the cancer types when compared to the primary cell lines
and tissues (Kolmogorov-Smirnov, P < 1 3 107). We discovered
that these hypomethylated loci were colocalized in the genome
and identified 114 independent megabase windows that had sig-
nificantly more hypomethylated loci than expected, taking into
account the nonrandom genomic coverage of the assay (Fisher’s
exact test, P = 2 3 105) (genomic coordinates listed in Supple-
mental Table S3). These megabase-size hypomethylated domains
were significantly depleted of genes (binomial, P < 3.48 3 1040)
and were significantly enriched in the 10-Mbp ends of chromo-
somes and near the centromere, although they are not usually
directly adjacent to the telomeres or centromeres (binomial, p =
4.41 3 1019) (Fig. 2A). Recent reports have found that some
tumors exhibit hypomethylation corresponding to lamina-
associated domains (Berman et al. 2012), but we did not observe an
enrichment for lamin B1 binding in the hypomethylated domains
we identified. It has also been reported that hypomethylated
regions in cancer correspond to H3K27me3 (Hon et al. 2012;
Statham et al. 2012), and we found that the domains we identi-
fied overlap long tracks of H3K27me3, as well as correspond-
ing stretches of EZH2 binding. We compared the presence of
H3K27me3 in these regions between cancer cell lines and non-
cancer cell lines and discovered that the long tracks of H3K27me3
were specific to the cancer cell lines (x2 test, P = 2.4 3 1027).
Brinkman et al. demonstrated that whenDNAmethyltransferases
are knocked-out in ESCs, broad local enrichments (BLOCs) of
H3K27me3 appear in place of high levels of methylation (Brinkman
et al. 2012). It is plausible that the same process is directing
H3K27me3 BLOC formation at these hypomethylated domains
in cancer. Among the ChIP-seq experiments comprising 149
transcription factors, we did not identify any factors that were
particularly enriched in these domains. Notably, these hypo-
methylated domains occasionally contain a gene that is ex-
pressed in specific cancer samples, and those samples exhibit
gene-body methylation within the hypomethylated domain
corresponding to the gene’s expression. This indicates that gene
expression and gene-body methylation are not occluded from
these regions by the unmethylated tracks of H3K27me3 sur-
rounding the gene. The prevalence of these domains across
cancer types warrants further investigation of these regions as
predictive biomarkers and to uncover the mechanisms driving
these massive defects. Figure 2B depicts an example of a domain
at the end of the q-arm of chromosome 22, where a 2-Mb gene-
depleted region is specifically hypomethylated across cancer
cell lines and exhibits long tracks of cancer-specific H3K27me3
and EZH2 binding. This hypomethylated domain is flanked by
methylation corresponding to the gene-body methylation of
expressed genes.
The single nucleotide resolution of bisulfite sequencing al-
lows us to detect both methylation and DNA sequence variants
in the same molecules, and we used this information to identify
loci with allele-specific or allele-biased methylation (Gertz et al.
2011). We identified 1144 CpGs that were adjacent to an allelic
variant and exhibited allele-biased methylation in the noncancer
samples from different tissues and individuals. We found that
1027 (90%) of these CpGs, which are allelically methylated in
noncancer samples, exhibit aberrant methylation in cancer cell
lines (Kolmogorov-Smirnov, FDR-adjusted, P < 0.05) (Supple-
mental Fig. S7A). This aberrant methylation occurs as either
hypermethylation (gain of methylation on the unmethylated
allele) (example in Supplemental Fig. S7B) or hypomethylation
(loss of methylation on the methylated allele) (example in
Table 1. Genomic context of cell-type specific methylation
CGI
Near TSS (<2 Kbp) Far from TSS in gene body Intergenic
Hypo Hyper Hypo Hyper Hypo Hyper
Cancer-specific + 78 (0.3%) 26,434 (99.7%) 130 (1.5%) 8701 (98.5%) 291 (2.1%) 13,652 (97.9%)
 673 (15.5%) 3657 (84.5%) 1628 (30.4%) 3720 (69.6%) 3890 (51.1%) 3716 (48.9%)
Blood-specific + 59 (4.2%) 1359 (95.8%) 103 (11.9%) 763 (88.1%) 50 (8.9%) 511 (91.1%)
 265 (28.3%) 673 (71.7%) 456 (29.9%) 1069 (70.1%) 360 (29.9%) 843 (70.1%)
Tissues vs.
primary cell lines
+ 71 (44.9%) 87 (55.1%) 257 (100%) 0 (0%) 43 (43.4%) 56 (56.6%)
 152 (33.7%) 299 (66.3%) 718 (100%) 0 (0%) 239 (43.1%) 316 (56.9%)
Varley et al.
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Supplemental Fig. S7C). Loss-of-imprinting has been previously
reported at particular imprinted loci in cancer (Feinberg et al. 2002;
Bjornsson et al. 2007; Feinberg 2007; Monk 2010), and these
observations demonstrate that the majority of allelically methyl-
ated loci are dysregulated in cancer, regardless of whether they are
imprinted.
Figure 2. Megabase-size domains are hypomethylated across cancers. (A) We identified 114 megabase windows in the genome that are significantly
hypomethylated across cancer cell lines, compared to primary cell lines and tissues. These domains are enriched near the ends and centromeres of
chromosomes. (B) UCSC Genome Browser visualization of a 2-Mb hypomethylated domain on the q-arm of chromosome 22. The color in the RRBS track
indicates the percent of molecules that are methylated at each CpG position. (Red) 100%, (yellow) 50%, (green) 0%. Hypomethylation across cancers
occurs in the 2-Mb gene-depleted region. RNA-seq demonstrates that the methylated regions flanking the cancer-specific hypomethylated domain
contain genes that are expressed in both the cancer (HeLa, HepG2, and K562) and noncancer samples (GM12878 and H1-HESC). The chromatin ChIP-seq
tracks demonstrate that the hypomethylated region is marked by cancer-specific repressive H3K27me3 and EZH2 binding (cancer = K562, HeLa, HepG2;
noncancer = HMEC, GM12878, NH-A).
Dynamic DNA methylation across human tissues
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Cell-type specific methylation
When we isolated and subjected noncancer samples to un-
supervised hierarchical clustering of the top 5% of CpGs with the
most variable methylation (N = 22,152, s $ 24.5), the samples
again clustered into clades corresponding to distinct types of bi-
ological samples: tissues, primary cell lines, embryonic cell lines,
and blood leukocytes (Fig. 3A; detailed tree in Supplemental Fig.
S8). The blood leukocyte-derived samples, including both periph-
eral blood leukocytes and Epstein-Barr virus (EBV)-immortalized
lymphoblastoid cell lines, clustered together and displayed a dis-
tinct pattern of methylation at 6511 CpGs (Kolmogorov-Smirnov,
P < 1 3 107). Blood-specific hypermethylation occurs at CGIs
(Table 1), but unlike the ubiquitous CGI methylation in cancer cell
lines, only a select subset of CGIs (66%) exhibit hypermethylation
when compared to tissue and primary cell lines. Epigenetic regula-
tion of genes involved in blood leukocyte development was evi-
dent and included specific methylation at genes involved
in regulation of body fluid levels (GO:0050878, P = 3.25 3 104),
blood coagulation (GO:0007596, P = 5.333 104), hematopoietic or
lymphoid organ development (GO:0048534, P = 8.523 104), and B
cell activation (GO:0042113, P = 9.24 3 104).
We identified seven tissue types that were represented by
both primary cell lines and primary tissues and performed ANOVA
to identify CpGs whose methylation is
significantly associated with the tissue of
origin (regardless of whether it has been
grown in culture). We identified 117,795
CpGs whose methylation was signifi-
cantly associated with the tissue of ori-
gin and was consistent in both the pri-
mary cell lines and the primary tissues
(FDR < 0.05) (subset visualized in Fig. 3B).
These data support previous observations
that there is a large number of tissue-
specific differentially methylated regions
(tDMRs) (Rakyan et al. 2008) and that
primary cell lines can serve as models for
understanding epigenetic tissue-specific
gene regulation at a large number of loci.
However, as described above, we found
that unsupervised hierarchical clustering
of the most variable CpGs across sam-
ples divided the primary cell lines from
the tissues (Figs. 1A, 3A). We identified
2238 CpGs that significantly discriminate
primary cell lines from tissue samples
(Kolmogorov-Smirnov, P < 1 3 107)
(Table 1; loci listed in Supplemental Ta-
ble S4). These methylation differences
associated with cell culture occur pre-
dominately as unmethylated CpGs in
the bodies of genes involved in regulat-
ing cellular proliferation (GO:0042127,
P = 5.17 3 104). Studies of DNA methyl-
ation that use cell lines as model systems
could use this list to reduce false positives
due to the epigenetic effects of cell culture.
Context-dependent DNA methylation
signatures of gene expression
The current models describing the rela-
tionship between DNA methylation and
gene expression indicate that promoter
methylation is associated with gene si-
lencing, and gene body methylation is
associated with expression (Doerfler et al.
1989; Jones and Baylin 2002; Lorincz
et al. 2004; Ball et al. 2009; Illingworth
et al. 2010;Maunakea et al. 2010;Aran et al.
2011; Deaton et al. 2011). RNA-seq has
been performed as part of The ENCODE
Project on several of the samples included
Figure 3. Noncancer samples exhibit methylation differences associated with cell culture, as well as
tissue-specific methylation that is preserved between primary cell lines and tissues. (A) Unsupervised
hierarchical clustering of the top 5% of CpGs with the most varying methylation across noncancer
samples separates clades of samples characterized as tissues, primary cell lines, embryonic cell types, and
blood leukocytes. The tissues and primary cell lines are divided into separate clades by a cell culture-
associatedmethylation signature. (B) Seven tissue types were represented by both primary cell lines and
tissues in this data set (tissue types listed in legend). ANOVA identified 117,795 CpGs significantly
associated with tissue of origin (FDR < 0.05). For this visualization, we performed unsupervised hier-
archical clustering on the 3223 significant CpGs with the largest standard deviation of PM values across
the samples (SD $ 26). Both primary cell lines and primary tissues share a common tissue-specific
methylation pattern, and the heat map displays the methylation patterns associated with each tissue of
origin. Many CpGs are partially methylated in the tissues (black = 50%) at loci where the cell lines are
completelymethylated (yellow = 100%), indicating that heterogeneity among the cell types comprising
the tissues results in a dampened signal compared to the pure cell population isolated in a cultured cell
line (tissues marked by *, cell lines unmarked).
Varley et al.
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in our DNA methylation study, providing an opportunity to ex-
plore and quantify this relationship. We divided the CpGs near
genes into four categories that were distinguished based on
whether or not they reside in CGIs and whether they are near the
TSS (<2 kb upstream or downstream) or far from the transcription
start site in the gene body ($2 kb). We computed the Pearson
correlation coefficient between RPKM values (reads per kilobase
of transcript per million reads) (Mortazavi et al. 2008) measured
by RNA-seq and PM values measured by RRBS. In this data set, the
vast majority of CpGs close to the TSS, regardless of whether they
reside in CGIs, are negatively correlated with gene expression
(median r =0.3756), i.e., increasedmethylation is associatedwith
lower levels of gene expression (Fig. 4A,B). In contrast, the nonis-
land CpGs far from the TSS in the body of the gene are positively
correlated with expression (median r = 0.44450), i.e., increased
methylation is associated with higher levels of gene expression
(Fig. 4D). For these promoter and nonisland gene body CpGs, the
current model of the relationship between methylation and ex-
pression holds across these cell lines. However, we also identified
an exception to the expected pattern: island CpGs residing in gene
bodies displayed a bimodal distribution of correlation with ex-
pression levels (Fig. 4C). This indicates that a substantial subset of
CGIs in the gene body are negatively correlated with expression,
similar to promoters, rather than positively correlated with expres-
sion like other gene body CpGs.
To investigate gene regulatory processes that could account
for this finding, we integrated data sets from The ENCODE Proj-
ect, including CAGE tag sequencing, histone modification, and
transcription factor ChIP-seq. Recent studies have proposed that
cryptic or alternative promoters, marked by H3K4me3 and CAGE
tags, may appear as promoter-like methylation in gene bodies
(Illingworth et al. 2010; Maunakea et al. 2010; Deaton et al. 2011).
We found that H3K4me3 and CAGE tags account for 8.5% (479/
6155) of the gene body CGI CpGs that were negatively correlated
with expression, providing evidence that this subset of CGIs in-
deed reside in alternative promoters (Fisher’s exact test, P-value =
1.06 3 107 [H3K4me3] and 0.009124
[CAGE tags]).
We sought to identify other function
elements that could explain the remain-
ing gene body CGIs that have epigenetic
regulation similar to promoters. A recent
study showed that DNA binding factors
influence DNA methylation and that the
methylation signature could be used to
identify CpG-poor distal enhancers in the
mouse genome (Stadler et al. 2011). The
causes and consequences of gene-body
methylation are not well understood,
making it unclear whether active en-
hancers could be unmethylated when
embedded in the densely methylated
gene body of an expressed gene. We in-
vestigated whether the unmethylated
CpG-rich regions that we observe within
methylated gene bodies might be in-
tragenic enhancers. We performed ChIP-
seq for the transcriptional coactivator
EP300, a factor known to bind to tran-
scriptional enhancers (Visel et al. 2009).
The vast majority of CpGs in EP300
binding sites were unmethylated (PM #
10; 99.3% inHepG2, 98.2% inGM12878,
99.6% in hESC H1). When gene body
CGIs contain EP300 binding sites, they
are more strongly inversely correlated
with gene expression than are CGIs not
bound by EP300 (Kolmogorov-Smirnov
test, P-value < 2.23 1016) (Supplemental
Fig. S9). These EP300-bound CGI in-
tragenic enhancers account for an addi-
tional 8% (452/5676) of gene body CGIs
that are negatively correlated with ex-
pression. The signature of CpG-rich ac-
tive enhancers in gene bodies was not
observed at CpG-poor regions, indicating
that this escape from gene-body methyl-
ation is associated with CGIs. To identify
other transcription factors associated
with these unmethylated gene body CpG
Figure 4. Correlation between CpGmethylation and gene expression depends on genomic context.
(A,B) CpGs <2000 bp away from the transcription start site (TSS) are negatively correlated with ex-
pression, regardless of whether they reside in a CpG island. (C ) CpGs that are in gene bodies far from the
TSS (>2000 bp away) and reside in CpG islands can be either positively or negatively correlated with
gene expression. (D) CpGs that are in the gene body far from the TSS (>2000 bp away) and do not reside
in CpG islands and are positively correlated with gene expression. (E ) Model of relationship between
methylation and gene expression. Expressed genes are associated with unmethylated promoters,
methylated gene bodies, and unmethylated intragenic CpG island EP300-bound enhancers. (F ) Si-
lenced genes are associated with methylated promoters, unmethylated gene bodies, and methylated
intragenic CpG island enhancer elements.
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islands that may reveal the role of the remaining loci that are not
associated with EP300 binding, H3K4me3, or CAGE tags, we over-
lapped them with the binding sites for the remaining 148 tran-
scription factors in ChIP-seq data sets generated by The ENCODE
Project Consortium. We did not identify any significant enrich-
ment for specific transcription factors. The catalog of EP300-bound
enhancers and other nonpromoter regulatory elements is not
comprehensive. It is possible that these are enhancers bound by
EP300 below the sensitivity of ChIP-seq, or they could be regu-
latory regions bound by transcription factors or noncoding RNAs
not yet studied by The ENCODE Project
Consortium.
Together, these results support a re-
vised model of the expected DNA meth-
ylation state found at expressed and si-
lenced genes, depicted in Figure 4, E and F.
In expressed genes, active intragenic
enhancers bound by EP300 appear as
patches of unmethylated CGIs amid the
dense methylation found in the body of
the expressed genes, and these enhancers
havemethylation that is concordantwith
the unmethylatedCpGs several thousand
base pairs away in the promoter and near
the TSS. The reverse patterns are associ-
ated with silenced genes. This revised
model changes our expectations of the
type of methylation we find in gene re-
gions and helps to more accurately in-
terpret gene body methylation.
Non-CpG cytosine methylation
DNA methylation predominately occurs
at CpG dinucleotides in the human ge-
nome, but there have been recent re-
ports that non-CpG cytosine methyla-
tion occurs at a lower, but appreciable,
level in embryonic and pluripotent cells
(Lister et al. 2009; Ziller et al. 2011). We
identified 56,287 cytosines that were
not located at CpG positions in the ref-
erence genome that exhibited methyla-
tion (PM > 10) in at least one sample. We
eliminated 30,773 (55%) of these meth-
ylated cytosines from further analysis
because they were adjacent to genetic
variants in these samples that created a
CpG dinucleotide that became methyl-
ated, a finding that suggests that there is
a large number of polymorphic CpGs that
show epigenetic diversity between in-
dividuals. To reduce false-positives due to
stochastic errors in bisulfite conversion,
we identified 2466 non-CpG cytosines
that were methylated (PM > 10) in both
replicates of any sample and determined
how many of these loci were methylated
in each sample (Supplemental Table S5;
data in Supplemental Table S6).We found
the largest number of methylated non-
CpG cytosines (N = 1418) in the human
embryonic stem cell line H1 (H1-hESC), consistent with previous
reports in this cell type (Fig. 5A). Adult human brain tissue had the
second highest number of methylated non-CpG cytosines, with
666 non-CpG cytosines methylated in both replicates, and was
more than twice as high as the following sample (Supplemental
Table S5). The non-CpG methylation we observed in the brain
samples occurred at a different set of loci than the non-CpG
methylation observed in ESCs (Fig. 5A). This was unexpected in
light of the recent report of the near complete absence of non-CpG
cytosine methylation in human somatic cell types, although adult
Figure 5. Non-CpG cytosine methylation. (A) We examined 82 cell lines and tissues and identified
2466 non-CpG cytosines that were methylated in both replicates. The samples with more than 200
methylated non-CpG cytosines are depicted. The human embryonic cell line (H1-hESC) contained 1418
methylated non-CpG cytosines, followed by adult human brain tissue (N = 666), placental tissue (N =
249), and skeletal muscle from two individuals (female N = 261, male N = 235). (B) The non-CpG
cytosine methylation identified in the brain tissue was confirmed across post-mortem brain samples
from 24 different individuals and occurs at a set of loci distinct from those methylated in the other
samples. (C ) The non-CpG cytosine methylation found in the embryonic stem cell line occurred pri-
marily at the CAG sequence context, consistent with previous reports (Lister et al. 2009). (D) The non-
CpG cytosine methylation discovered in the adult human brain tissue occurred primarily in the CACC
sequence context.
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human brain tissue was not studied (Ziller et al. 2011). The ob-
servation of non-CpG methylation in somatic tissues challenges
current hypotheses that a pluripotent-specific regulation or noise
is involved in establishing this mark. The other samples withmore
than 200 non-CpG cytosines methylated in both replicates in-
cluded skeletal muscle tissue from two different individuals and
placental tissue (Fig. 5A; Supplemental Table S5). To further in-
vestigate non-CpG cytosine methylation in the brain, we per-
formed RRBS on brain samples from 24 additional individuals.
These fresh-frozen samples were collected post-mortem from the
dorsolateral prefrontal cortex (DLPFC) of healthy control donors as
part of the Pritzker Neuropsychiatric Disorders Research Consor-
tium. The non-CpG cytosines that were methylated in the first
brain sample were also methylated (PM > 10) in these additional
brain samples (Fig. 5B; data in Supplemental Table S7). The non-
CpG loci that are methylated in adult brain tissue are distinct from
the set of non-CpG cytosines that were methylated in ESCs (Fig.
5B). The non-CpG cytosine methylation that we observed in the
brain predominately occurs at CAC trinucleotides (Fig. 5D), which
is different from the CAG trinucleotide context that we and others
have observed in ESCs (Fig. 5C; Lister et al. 2009; Ziller et al. 2011).
Non-CpG methylation was recently reported in mouse frontal
cortex (Xie et al. 2012) in a similar sequence context that we find in
human brain, suggesting that mice may serve as a valuable
experimental model for understanding this new methylation
pattern. We used GREAT (Genomic Regions Enrichment of An-
notations Tool) (McLean et al. 2010) to determine if these meth-
ylated non-CpG cytosines are associated with any functional en-
richment and found that loci in brain tissue are found near genes
enriched for ‘‘blood vessel development’’ (GO:0001568, GREAT
hyper FDR q-val = 5.343 106), while the loci methylated in hESC
are found near genes related to small GTPase regulator activity
(GO:0005083 hyper FDRq-val =4.913 104), suggesting that these
events are associated with different gene regulatory processes in
each cell type.
Discussion
We have described an epigenomics resource generated by the
ENCODE Consortium: large-scale single-base resolution DNA
methylation profiling on a diverse collection of 82 human cell
lines and tissues using reduced representation bisulfite sequenc-
ing. Many of these samples have been characterized with other
genomic assays by The ENCODE Project Consortium, providing
a rich resource for exploring functional changes associated with
DNA methylation. We demonstrated that cell lines grown in rep-
licate in multiple laboratories display stable DNA methylation
signatures, that comparingmethylation profiles between samples
identifies methylation profiles relevant to the functional differ-
ences between cell types, and that these data provide a catalog of
aberrant methylation found in cancer cell lines.
We discovered that cancer-specific hypermethylation is en-
riched at sites where NANOG binds in ESCs. This observation
complements the previous report of a stem/progenitor signature
in cancer but expands it beyond loci that are bound by Polycomb
Repressive Complex 2 to include loci that are bound and activated
by NANOG, a seemingly contradictory process. Further investi-
gation is needed to understand when, during the progression of
cancer, NANOG is present andhowwould it attract themethylation
machinery to result in this aberrant hypermethylation. Addition-
ally, we discovered that hypomethylation that is consistent across
cancer types occurs in megabase-scale domains near the ends of
chromosomes that contain long tracks of cancer-specific repres-
sive H3K27me3. Further investigation is needed to understand
how and why H3K27me3 repression is utilized in these regions
rather than DNA methylation and whether their location on the
ends of chromosomes is indicative of a structural mechanism
or scaffold interaction that leads to their hypomethylation. As
more genome-scale assays are performed on these samples, we are
hopeful that further integrated analysis will shed light on the
causes and consequences of these prolific methylation defects in
cancer.
We demonstrate how integrated analysis enabled the quan-
tification of known relationships between DNA methylation and
gene expression and describe the characterization of DNA meth-
ylation at intragenic enhancers. We present a revised model of the
types of methylation found in the body of expressed and silenced
genes that includes our finding that unmethylated EP300-bound
CGIs can be embedded in the densely methylated bodies of
expressed genes. Thismodel can be used tomore accurately predict
the effects of aberrant DNA methylation found in disease associ-
ation studies where EP300 binding and gene expression data are
not available.
The single-base resolution of RRBS enabled the detection of
non-CpGs cytosine methylation across the diverse samples in this
study, which led to the discovery that adult human brain tissue
from many different individuals contains methylated non-CpG
cytosines. We find that these loci are different from those pre-
viously identified in ESCs and occur in a CACC sequence con-
text, rather than at CAG trinucleotides. This data set provides a
launching point for the investigation of the mechanisms and
function of this newly characterized phenomenon. It is intrigu-
ing that this mark is particularly abundant in brain tissue but
not in the brain-derived cell lines in our study. It is plausible that
the non-CpG methylation occurs in a particular type of brain cell
that was not among the cell lines in this study or that the non-
CpG methylation is eliminated during cell culture growth. As
more genomic assay protocols are adapted to work with small
amounts of tissue, we are hopeful that cell types and factors as-
sociated with the non-CpG methylation at these loci will be
revealed.
Overall, we hope that this atlas of methylation across diverse
samples, including many commonly used cell line models, proves
to be a valuable resource for exploring how DNA methylation re-
lates to other molecular and phenotypic characteristics.
Methods
Cell lines and tissues
Samples included in this study are listed in Supplemental Table S1.
Detailed information about the samples can be obtained from the
ENCODE Common Cell Types websites at (http://genome.ucsc.
edu/ENCODE/cellTypes.html).
Reduced representation bisulfite sequencing experimental
procedure
Wemodified the previously published protocol for RRBS (Meissner
et al. 2008) to create a streamlined workflow for this larger-scale
implementation. We designed the reactions to eliminate the
phenol extraction and ethanol precipitation steps as well as one of
the gel extraction steps. We also changed the PCR conditions to
amplify fragments with diverse GC content and a broad range of
sizes uniformly. A protocol overview is depicted in Supplemental
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Figure S1, and specifics are provided as follows.Weused theQiagen
DNeasy Blood and Tissue Kit to extract DNA. We then digested
1 mg genomic DNA with 1 mL 20U/mL MspI restriction enzyme
(New England Biolabs [NEB]) in 13 NEBuffer 2 in a total reaction
volume of 50 mL. This reaction was incubated at 37°C for 30 min,
followed by heat inactivation at 80°C for 20min.We then filled in
the overhangs and added a 39 A tail by adding dNTP mix to 33 mM
and 1 mL 5U/ mL Klenow Fragment (39–59 exo-) in a total reaction
volume of 55 mL. This reaction was incubated at 37°C for 30 min,
followed by heat inactivation at 75°C for 20min.We then purified
the DNA with a Qiagen MinElute column. We purchased two
methylated DNA oligonucleotides from IDT (www.idtdna.com) as
follows: ilAdap Methyl PE1 (ACACTCTTTCCCTACACGACGCT
CTTCCGATC*T) and ilAdap Methyl PE2 (59P-GATCGGAAGAG
CGGTTCAGCAGGAATGCCGA*G), where all C’s are 5-methyl
cytosine DNA nucleotides, 59P indicates a 59 phosphate, and an
asterisk indicates a phosphorothioate bond. We then annealed
these oligos to form a stock of 40 mM duplex DNA adapters in
a reaction containing 40 mM ilAdap Methyl PE1, 40 mM Methyl
PE2, 13 T4DNA Ligase Buffer (NEB) in a total volume of 50 mL.We
incubated this reaction at 95°C for 5 min, then 70°C for 1 min,
then 60°C for 1 min, then 50°C for 1 min, then 40°C for 1 min,
then 30°C for 1 min. We stored these annealed adapters at 30°C
for future use. We ligated the annealed methylated Illumina
adapters in a reaction containing 10 mL purified DNA, 13 T4 DNA
Ligase Buffer (NEB), 1 mL 400U/mL T4 DNA Ligase (NEB), and 1 mL
40 mM annealed methylated adapters in a total volume of 20 mL.
This reaction was incubated at 20°C for 15 min, followed by heat
inactivation at 65°C for 10 min. We electrophoresed the 20 mL li-
gation reaction in a 2.5% Seaplaque Agarose (Lonza) gel. The de-
sired restriction fragments are between 40 and 120 bp, and the
adapters add 33 bp onto each end of the restriction fragments, so
we used a razor blade to isolate the agarose gel section containing
DNA between 106 and 186 bp, while avoiding the adapter self-
ligation products that appear <100 bp. We then purified the DNA
using a Qiagen Qiaquick Gel Extraction kit as described in the
manufacturer’s instructions, except that we did not heat the gel
fragment to dissolve it, and we eluted the purified DNA from the
column using 22 mL buffer EB. We then used 20 mL of this purified
DNA in the sodium bisulfite conversion, which was performed
using the EZ DNA Methylation Gold Kit (Zymo Research). We
purchased PCR primers that would amplify the adapter-ligated
DNA and add the cluster generation sequences to the amplicons
for Illumina sequencing. We purchased these PCR primers from
IDT as follows: ilPCR PE1 (AATGATACGGCGACCACCGAGATC
TACACTCTTTCCCTACACGACGCTCTTCCGATC*T) and ilPCR
PE2 (CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCC
TGCTGAACCGCTCTTCCGATC*T), where an asterisk indicates
a phosphorothioate bond. The DNA that was purified from the
bisulfite conversion kit was then PCR-amplified in a reaction
containing 5 U Platinum Taq DNA Polymerase (Invitrogen), 103
PCR Buffer without MgCl2 (Invitrogen), 2 mM MgCl2, 0.5 mM
ilPCR PE1 DNA oligonucleotide primer, 0.5 mM ilPCR PE2 DNA
oligonucleotide primer, 0.5 mM each dNTP and 0.5 M Betaine
(Sigma-Aldrich) in a total reaction volume of 50 mL. The reaction
was incubated at 98°C for 1min, followed by 20 cycles of (95°C for
30 sec and 62°C for 3 min). We confirmed the amplification and
correct product size range by running one-fifth of the reaction on
a 2% agarose gel. We then purified the remaining PCR product
with a Qiagen Qiaquick column, eluting in 25 mL buffer EB, and
quantified the purified product using the Quant-IT High Sensi-
tivity dye kit (Invitrogen) on a Qubit fluorometer (Invitrogen). We
typically obtained 250–750 ng of library material. We then diluted
each library to 10 nM and proceeded to sequence each library in
a single lane on the Illumina Genome Analyzer IIx sequencing
machine according the manufacturers instructions. We typically
achieved better quality scores and alignment with slightly lower
cluster density compared to other libraries with more even base-
representation, and we empirically determined that clustering the
sample at 5 pM was optimal.
Sequence alignment and calculating percent methylated value
for each cytosine
The sequence data for this project were acquired between June
2009 and December 2010. On our Illumina Genome Analyzer IIx
sequencing machine, we sequenced one library per lane and
obtained between 8 million and 31 million single-end 36-bp reads
per library. We aligned these reads to a modified reference genome
sequence that was created to reflect both the reduced representa-
tion of the genome due to the MspI restriction digest as well as the
sodium bisulfite conversion which creates a T in the sequencing
reads rather than a C at all unmethylated bases. To create this
reference, we first parsed the hg19 reference genome to identify all
of the MspI restriction fragments <500 bp. We then isolated the
36-bp ends of these fragments into a fasta file and converted every
C in the reference to a T and recorded the position of these refer-
ence cytosines in the name of the reference sequence. To achieve
optimal alignment that is not biased by the methylation state of
a molecule, we also created a copy of our sequencing read files,
converted every C in the read to a T, and recorded the position of
these read cytosines in the nameof the read (Supplemental Fig. S2).
We then used bowtie (Langmead et al. 2009) to align these con-
verted reads to the custom reference sequence and required that
the alignment be optimal and unique in the reference and only
align to the proper strand (bowtie options –best, -m 1,–norc). On
average, we uniquely aligned 53.2% (200,000/375,603) of the ge-
nomic MspI digest restriction fragments in the selected size range
(40–120 bp), which resulted in coverage of an average of 1.2 mil-
lion CpGs in each sample. This is only 8.6% of the 14 million
nonrepetitive CpGs in the human genome but represents a 1.9-
fold enrichment for genic regions and a 111-fold enrichment for
CGIs. We then parsed the alignment file and the encoded read and
reference names to determine how many reads covered each ref-
erence cytosine position and what percentage of those reads con-
tained a C at each reference cytosine position (Supplemental Fig.
S2). This percentmethylated value approximates the percentage of
molecules in the sample that were methylated at each individual
cytosine. We compute the bisulfite conversion rate of each sample
by determining the percent of non-CpG cytosines that are meth-
ylated (PM$ 10), which is an underestimate of the conversion rate
in samples with biological non-CpG methylation. Each sample
must meet quality control criteria before data release, including
a bisulfite conversion rate $98.5%, a complex library with more
than 500,000 CpGs with at least 103 coverage, and a correlation
coefficient of greater than 0.9 between replicates.
Methyl 450 array methods
Illumina Methylation450 arrays were run using standard Illumina
protocols. Briefly, 500 ng of DNA from each cell line was bisulfite-
converted with the Zymo Research EZ DNA Methylation kit, ampli-
fied, hybridized, and stained with standard Illumina reagents. The
intensity datawere imported into Illumina’sGenomeStudio software,
and standard beta scores were exported and used in the analysis.
Analysis of methylation across samples
Once we compiled the percent methylated values for all cytosines
shared across samples, we then performed extensive analysis of the
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trends in these data. Statistical associations including mean cal-
culations, standard deviation calculations, Pearson correlations,
binomial tests, Fisher’s exact tests, x2 tests, hypergeometric tests,
and Kolmogorov-Smirnov tests were calculated using Matlab
(The Mathworks, Inc.), and the statistical package R (The R Foun-
dation for Statistical Computing; http://www.R-project.org). Clus-
tergrams were created using the average linkage of Euclidean dis-
tance in Cluster3.0 (de Hoon et al. 2004) and visualized using
Java TreeView 1.1.4r3 (Saldanha 2004). For the annotation of cy-
tosine positions relative to gene features, we used the genomic
coordinates for gene features from the hg19 refGene table of the
UCSC Genome Browser (Fujita et al. 2011; Raney et al. 2011).
Similarly, we used the genomic positions of the CpG islands track
on the UCSC Genome Browser to annotate CGI occupancy. To
measure the Pearson correlation between methylation and ex-
pression, we excluded CpGswhosemethylation did not vary by 10
PM across the cell lines to avoid spurious correlations to noise in
the methylation measurements. For identifying transcription fac-
tor binding sites associated with loci hypermethylated across
cancer cell lines, we used the compiled supertrack data set con-
taining binding sites for 149 transcription factors from ENCODE
ChIP-seq experiments, which is available from the UCSC Genome
Browser (http://www.genome.ucsc.edu/cgi-bin/hgTrackUi?hgsid=
305048059&c=chr2&g=wgEncodeRegTfbsClusteredV2). For ana-
lyzing the binding sites of the specific transcription factors, we
used individual ChIP-seq data sets. The data for SUZ12 binding
sites in H1-hESC are available from the UCSC Genome Browser
(http://www.genome.ucsc.edu/cgi-bin/hgTrackUi?hgsid=305048059&
g=wgEncodeSydhTfb). The data for NANOG binding sites in H1-
hESC are also available from the UCSC Genome Browser (http://
www.genome.ucsc.edu/cgi-bin/hgTrackUi?hgsid=305048059&
g=wgEncodeHaibTfbs). For characterizing the hypomethylated
domains found across cancer cell lines, we used the H3K27me3
and EZH2 binding ChiP-seq data collected by the Broad Institute
as part of The ENCODE Project, which were obtained from the
UCSC Genome Browser (http://www.genome.ucsc.edu/cgi-bin/
hgTrackUi?hgsid=286312585&c=chr4&g=wgEncodeBroadHistone).
The nuclear lamina-associated domains data were obtained from
the UCSC Genome Browser (http://www.genome.ucsc.edu/cgi-bin/
hgTrackUi?hgsid=305048059&c=chr2&g=laminB1Super). The
RNA-seq data for the HeLa, hESCH1, K562, HepG2, and GM12878
cell lines were collected as part of The ENCODE Project and can
be found under ‘‘RNA-seq from ENCODE/Caltech’’ on the UCSC
Genome Browser (http://genome.ucsc.edu/cgi-bin/hgTrackUi?hgsid=
193248635&c=chr10&g=wgEncodeCaltechRnaSeq). The H3K4me3
ChIP-seq data for the HeLa, K562, HepG2, and GM12878 cell
lines were collected as part of The ENCODE Project and can be
found under ‘‘Histone Modifications by ChIP-seq from ENCODE/
University of Washington’’ on the UCSC Genome Browser (http://
genome.ucsc.edu/cgi-bin/hgTrackUi?hgsid=203697013&c=chr5&g=
wgEncodeUwHistone). The CAGE tag data from whole cell polyA+
fractions of the HeLa, hESC H1, K562, HepG2, and GM12878 cell
lines were collected as part of The ENCODE Project and can be
found under (http://genome.ucsc.edu/cgi-bin/hgTrackUi?hgsid=
210114571&c=chr21&g=wgEncodeRikenCage). The EP300 ChIP
binding site information was generated by our group as part of The
ENCODE Project and can be found under ‘‘ENCODE Transcription
Factor Binding Sites by ChIP-seq from HudsonAlpha Institute’’
on the UCSC Genome Browser (http://genome.ucsc.edu/cgi-bin/
hgTrackUi?hgsid=210114571&c=chr21&g=wgEncodeHaibTfbs).
Binding sites for EP300 identified in GM12878, H1 hESC and
HepG2 were combined to create a list of potential enhancers. Ge-
netic polymorphism that created CpG dinucleotides were identified
as those positions where the bowtie alignment identified the same
mismatched base in at least 10% of the reads with a minimum read
depth of five. Functional annotation and enrichment of genes was
obtained using the gene ontology search program Gorilla (http://
cbl-gorilla.cs.technion.ac.il/) (Eden et al. 2009), using the option
that calculates enrichment in a target gene list over a background list
of all genes covered in the RRBS libraries. The motif logos repre-
senting the sequence context of non-CpG cytosine methylation
were created using WebLogo (http://weblogo.berkeley.edu) (Crooks
et al. 2004).
Data access
The DNA methylation data generated as part of The ENCODE
Project are available for visualization and download from the
UCSC Genome Browser (GRCh37/hg19) (http://www.genome.
ucsc.edu) under the Regulation heading in the ENCODE DNA
Methylation tracks. All of the RNA-seq and ChIP-seq data used
in the analysis are also available for visualization and download
from the UCSC Genome Browser (links are listed in Supplemental
Table S1). The DNA methylation data are also available from the
NCBI Gene ExpressionOmnibus (GEO) (http://www.ncbi.nlm.nih.
gov/geo/) through accession numbers GSE27584 and GSE42590.
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